Wordt geladen...
Phase 3 Efficacy (Worse-Eye Analysis) and Long-Term Safety Evaluation of OTX-101 in Patients with Keratoconjunctivitis Sicca
BACKGROUND: OTX-101 is approved for treatment of keratoconjunctivitis sicca (KCS). We present results of a phase 3 worse-eye efficacy analysis and 1-year safety extension. METHODS: During the double-masked treatment phase, patients with bilateral KCS were randomized 1:1 to 12 weeks OTX-101 or vehicl...
Bewaard in:
| Gepubliceerd in: | Clin Ophthalmol |
|---|---|
| Hoofdauteurs: | , , , , , |
| Formaat: | Artigo |
| Taal: | Inglês |
| Gepubliceerd in: |
Dove
2021
|
| Onderwerpen: | |
| Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7811471/ https://ncbi.nlm.nih.gov/pubmed/33469259 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/OPTH.S279364 |
| Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|